Innovation supports revenue growth acceleration in Q3
. - Revenue growth for Q3 accelerated to 5.5% (CER) lifting revenue for the first nine months to EUR 416.7 million (up…
. - Revenue growth for Q3 accelerated to 5.5% (CER) lifting revenue for the first nine months to EUR 416.7 million (up…
. - Revenue for the first quarter of EUR 138.8 million was up 2.8% at constant exchange rates (CER) and down 1.9% in EU…
. - Revenue for Q3 was up 4.8% at constant exchange rates (CER) driving year-to-date revenue up 1.6% at CER to EUR 417.…
. - Revenue for the second quarter was up 2.3% at constant exchange rates (CER) driving revenue for the first half to E…
Nobel Biocare announced today the continuation of its functional re-alignment program, affecting primarily the corporate…
. - Revenue for the first quarter of EUR 141.5 million was down 2.0% at constant exchange rates (CER) and down 4.1% in…
. - Revenue for the full year 2012 was up 2.0% versus prior year to EUR 580.5 million and down 2.7% at constant exchang…
. - Revenue for the first nine months was up 3.1% to EUR 427.5 million versus prior year and down 2.4% at CER - Revenu…
Today Nobel Biocare (NOBN) announced preliminary revenue for the first nine months of EUR 427.5 million, up 3.1% in euro…
. - Revenue for the first six months of EUR 296.5 million was up 3.5% in EUR versus prior year and down 1.2% at CER - i…